Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs. Zanubru…
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Ibrutinib monotherapy showed durable progression-free survival in patients with TP53 aberrations or advanced age.
Ten Years on One Pill: What Long-Term Ibrutinib Revealed
This investigator-sponsored phase 2 study evaluated single-agent ibrutinib in 84 patients with chronic lymphocytic leukemia (CLL) harboring …
A decade of follow-up shows a daily pill can give high-risk leukemia patients years of control, but staying on it is not easy.
Case report: obinutuzumab and venetoclax associated with nephrotic syndrome resolution in two CLL patients
Two CLL patients saw kidney condition improve after targeted cancer treatment
A case report describes two patients with chronic lymphocytic leukemia (CLL) and concomitant nephrotic syndrome. Both patients showed clinic…
Two CLL patients saw kidney problems improve after targeted cancer treatment, resolving symptoms and reducing urine protein within weeks.